Country: Ireland
Bahasa: Inggeris
Sumber: HPRA (Health Products Regulatory Authority)
FLUVASTATIN SODIUM
Actavis Group PTC ehf
80 Milligram
Tablet Prolonged Release
2009-01-23
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Luvinsta XL 80 mg prolonged-release tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One prolonged-release tablet of Luvinsta XL contains 84.48 mg fluvastatin sodium equivalent to 80 mg fluvastatin free acid. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged-release tablet Yellow, round, biconvex tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dyslipidaemia Treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Secondary prevention in coronary heart disease Secondary prevention of major adverse cardiac events in adults with coronary heart disease after percutaneous coronary interventions (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults Dyslipidaemia Prior to initiating treatment with Luvinsta XL patients should be placed on a standard cholesterol-lowering diet, which should be continued during treatment.. Starting and maintenance doses should be individualized according to the baseline LDL-C levels and the treatment goal to be accomplished. The recommended dosing range is 20 to 80 mg/day. For patients requiring LDL-C reduction to a goal of < 25% a starting dose of 20 mg of fluvastatin may be used, administered in the evening. For patients requiring LDL-C reduction to a goal of ≥25%, the recommended starting dose is 40 mg of fluvastatin in the evening. The dose may be uptitrated to 80 mg daily, administered as a single dose (one Luvinsta XL prolonged-release tablet) at any time of the day or as 40 mg of fluvastatin given twice daily (in the morning and in the evening). Luvinsta XL is only availabl Baca dokumen lengkap